CLINICAL RESEARCH
Clinicopathologic and immunohistochemical features of gastrointestinal stromal tumors: a single-center experience
1
Department of Gastrointestinal Surgery, Kosuyolu Education and Research Hospital, Istanbul, Turkey
Submission date: 2019-11-27
Acceptance date: 2020-02-09
Publication date: 2020-03-09
Arch Med Sci Civil Dis 2020;5(1):8-13
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Here we present our 10-year experience regarding gastrointestinal stromal tumors (GISTs) in terms of clinicopathologic features and immunohistochemical staining patterns.
Material and methods:
In this single-center retrospective study, during 2008–2018, data of 26 patients with histologically confirmed diagnoses of GISTs were collected. All patients included in the study underwent surgical resection. The Mann-Whitney U test was used for continuous variables.
Results:
The mean age of the patients was 60.7 ±10.4 (35–79) years. The most common GIST location was the stomach (88.5%). The mean tumor size was 5.8 cm (1–13 cm) and the most common histologic type of GIST was spindle cell (61.5%). CD 117(c-kit) was positive in 96% of GIST cases, while CD34 was positive in 84.6%, discovered on GIST-1(DOG1) in 46.2%, smooth muscle actin (SMA) in 26.9%, S100 in 19.2%, and desmin in 7.7%. In one CD117 negative patient, DOG1 was positive. Four patients had metastases (15.4%). The mean follow-up time was 56.5 ±36.2 month. The length of hospital stay was significantly longer in patients who had small intestinal GIST (p = 0.010). In immunohistochemical staining, SMA was significantly more common among spindle cell type (p = 0.032).
Conclusions:
GISTs are very rare tumors of the gastrointestinal tract, but the accurate diagnosis with immunohistochemical staining is vital for the treatment. So, large scale, prospective and randomized multicenter trials are needed to reduce the misdiagnosis rate of GISTs.
Here we present our 10-year experience regarding gastrointestinal stromal tumors (GISTs) in terms of clinicopathologic features and immunohistochemical staining patterns.
Material and methods:
In this single-center retrospective study, during 2008–2018, data of 26 patients with histologically confirmed diagnoses of GISTs were collected. All patients included in the study underwent surgical resection. The Mann-Whitney U test was used for continuous variables.
Results:
The mean age of the patients was 60.7 ±10.4 (35–79) years. The most common GIST location was the stomach (88.5%). The mean tumor size was 5.8 cm (1–13 cm) and the most common histologic type of GIST was spindle cell (61.5%). CD 117(c-kit) was positive in 96% of GIST cases, while CD34 was positive in 84.6%, discovered on GIST-1(DOG1) in 46.2%, smooth muscle actin (SMA) in 26.9%, S100 in 19.2%, and desmin in 7.7%. In one CD117 negative patient, DOG1 was positive. Four patients had metastases (15.4%). The mean follow-up time was 56.5 ±36.2 month. The length of hospital stay was significantly longer in patients who had small intestinal GIST (p = 0.010). In immunohistochemical staining, SMA was significantly more common among spindle cell type (p = 0.032).
Conclusions:
GISTs are very rare tumors of the gastrointestinal tract, but the accurate diagnosis with immunohistochemical staining is vital for the treatment. So, large scale, prospective and randomized multicenter trials are needed to reduce the misdiagnosis rate of GISTs.
REFERENCES (30)
1.
Duensing A, Heinrich MC, Fletcher CD, Fletcher JA. Biology of gastrointestinal stromal tumors: KIT mutations and beyond. Cancer Invest 2004; 22: 106-16.
2.
Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152: 1259-69.
3.
Schaefer IM, Mariño-Enríquez A, Fletcher AJ. What is new in gastrointestinal stromal tumor? Adv Anat Pathol 2017; 24: 259-67.
4.
Hwang SJ, Blair PJ, Britton FC, et al. Expression of anoctamin 1/TMEM16A by interstitial cells of Cajal is fundamental for slow wave activity in gastrointestinal muscles. J Physiol 2009; 587: 4887-904.
5.
Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumors. Lancet 2007; 369: 1731-41.
6.
Miettinen M, Lasota J. Gastrointestinal stomral tumors. Gastroenterol Clin North Am 2013; 42: 399-415.
7.
Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008; 39: 1411-9.
8.
Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29: 52-68.
9.
Lai EC, Lau SH, Lau WY. Current management of gastrointestinal stromal tumors – a comprehensive review. Int J Surg 2012; 10: 334-40.
10.
Miettinen M, Fletcher CDM, Kindblom LG, Tsui WMS. Mesenchymal tumors of the stomach. In: WHO classification of tumors of the digestive system. 4th edn. Bosman FT, Carneiro F, Hruban RH, Theise ND (eds). IARC, Lyon 2010; 74-9.
11.
Miettinen M, Makhlouf H, Sobin LH, et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006; 30: 477-89.
12.
Kern A, Görgens H, Dittert DD, et al. Mutational status of KIT and PDGFRA and expression of PDGFRA are not associated with prognosis after curative resection of primary gastrointestinal stromal tumors (GISTs). J Surg Oncol 2011; 104: 59-65.
13.
Tan CB, Zhi W, Shahzad G, Mustacchia P. Gastrointestinal stromal tumors: a review of case reports, diagnosis, treatment, and future directions. ISRN Gastroenterol 2012; 2012: 595968.
14.
Kang GH, Srivastava A, Kim YE, et al. DOG1 and PKC-θ are useful in the diagnosis of KIT-negative gastrointestinal stromal tumors. Mod Pathol 2011; 24: 866-75.
15.
Sui XL, Wang H, Sun XW. Expression of DOG1, CD117 and PDGFRA in gastrointestinal stromal tumors and correlations with clinicopathology. Asian Pacific J Cancer Prev 2012; 13: 1389-93.
16.
Kiśluk J, Zińczuk J, Kemona A, et al. Expression of CD117, DOG-1, and IGF-1R in gastrointestinal stromal tumours – an analysis of 70 cases from 2004 to 2010. Gastroenterology Rev 2016; 11: 115-22.
17.
Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 2002; 38 (Suppl 5): S39-51.
18.
Kapoor R, Khosla D, Kumar P, Kumar N, Bera A. Five-year follow up of patients with gastrointestinal stromal tumor: recurrence-free survival by risk group. Asia Pac J Clin Oncol 2013; 9: 40-6.
19.
Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis and differential diagnosis. Arch Pathol Lab Med 2006; 130: 1466-78.
20.
Goh BK, Chow PK, Yap WM, et al. Which is the optimal risk stratification system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria. Ann Surg Oncol 2008; 15: 2153-63.
21.
Güler B, Özyılmaz F, Tokuç B, Can N, Taştekin E. Histopathological feautures of gastrointestinal stromal tumors and the contribution of DOG1 expression to the diagnosis. Balkan Med J 2015; 32: 388-96.
22.
Fujimoto Y, Nakanishi Y, Yoshimura K, Shimoda T. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer 2003; 6: 39-48.
23.
Nagasako Y, Misawa K, Kohashi S, et al. Evaluation of malignancy using Ki-67 labeling index for gastric stromal tumor. Gastric Cancer 2003; 6: 168-72.
24.
Özgüç H, Yilmazlar T, Yerci Ö, et al. Analysis of prognostic and immunohistochemical factors in gastrointestinal stromal tumors with malignant potential. J Gastrointest Surg 2005; 9: 418-29.
25.
Bülbül DG. Gastrointestinal stromal tumors: a multicenter study of 1160 Turkish cases. Turk J Gastroenterol 2012; 23: 203-11.
26.
Jumniensuk C, Charoenpitakchai M. Gastrointestinal stromal tumor: clinicopathological characteristics and pathologic prognostic analysis. World J Surg Oncol 2018; 16: 231.
27.
Hashimi AA, Faraz M, Nauman Z, et al. Clinicopathologic features and prognostic grouping of gastrointestinal stromal tumors (GISTs) in Pakistani patients: an institutional perspective. BMC Res Notes 2018; 11: 457.
28.
Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S. Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002; 33: 669-76.
29.
Rauf F, Bhurgri Y, Pervez S. Gastrointestinal stromal tumors: a demographic, morphologic and immunohistochemical study. Indian J Gastroenterol 2007; 26: 214-6.
30.
Kim MK, Lee JK, Park ET, et al. Gastrointestinal stromal tumors: clinical, pathologic features and effectiveness of new diagnostic criteria. Korean J Gastroenterol 2004; 43: 341-8.
| ISSN: | 2451-0637 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
